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Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the liver in the absence of alcohol abuse or other chronic liver diseases. Nonalcoholic fatty liver disease has been recognized as a hepatic manifestation of the metabolic syndrome 2 and is associated with several CV risk factors including hypertension, diabetes, atherogenic dyslipidemia, central obesity, and hyperuricemia. [3] [4] [5] [6] [7] Furthermore, NAFLD has been related to increased prevalence and severity of CHD. 8, 9 Apart from CV (and liver) morbidity, NAFLD and especially its advanced form, that is, nonalcoholic steatohepatitis (NASH) are associated with increased CV and total mortality. [9] [10] [11] Nonalcoholic fatty liver disease has also been linked to subclinical CV disease as assessed by coronary artery calcification, increased carotid intima-media thickness (cIMT), endothelial dysfunction, and arterial stiffness. 12 Of note, peri-and pararenal fat thickness appears to predict the presence and extent of a fatty liver. 13 Excessive epicardial fat has also been associated with increased CV risk. [14] [15] [16] Furthermore, increased epicardial fat can predispose to heart failure, 17, 18 atrial fibrillation, 19 and sudden cardiac death. 20 In this context, several adipocytokines secreted by epicardial fat can affect coronary endothelial cells, cardiomyocytes, fibroblasts, and smooth muscle cells resulting in cardiac dysfunction. 17, 21 Epicardial and pericardial fat also differ in fatty acid composition. 22 Further research is needed to elucidate the exact mechanisms linking these excessive cardiac fat depots with CV risk.
Manno et al 23 reported that epicardial and perirenal fat were simultaneously increased in uncomplicated overweight/obese individuals, supporting the coexistence of >1 excessive fat depots in such patients. From a developmental point of view, there are 6 visceral adipose tissues: epicardial, perirenal, retroperitoneal, gonadal, mesenteric, and omental. 24 All these 6 fat depots have a mesothelial layer similar to the visceral organs which includes cells enriched in white adipose tissue progenitors that can produce adipocytes. These data highlight the potential interrelationship between epicardial and perirenal fat.
Limited, but increasing data exist regarding pancreatic fat infiltration (nonalcoholic fatty pancreatic disease [NAFPD]). 25 Nonalcoholic fatty pancreatic disease has been mainly associated with acute pancreatitis, insulin resistance and type 2 diabetes mellitus, and pancreatic cancer, 25 whereas its relationship with CV risk has not been widely investigated yet. However, there are data linking NAFPD with NAFLD and CV disease. [26] [27] [28] To our knowledge, no studies have evaluated the coexistence of perirenal fat and NAFPD.
Perivascular adiposity may also play a role in the pathogenesis of cardiometabolic diseases. 29 Perivascular fat has been reported to exert vasoregulatory effects in the capillaries of skeletal muscles, thus contributing to insulin resistance, as well as to the production of cytokines that promote inflammation and endothelial dysfunction. 29 Of note, periaortic adipose tissue could be related to atherosclerosis (assessed by increased cIMT), whereas peribrachial adipose tissue could be associated with insulin sensitivity. 30 Furthermore, animal studies have shown that high-fat feeding can upregulate pro-inflammatory gene expression in perivascular adipose tissues. 31 The association between perirenal and perivascular fat depots has not been explored yet.
Intramuscular fat, accumulating either within muscle cells or between muscle fibers, has been linked to cardiometabolic risk factors such as dyslipidemia, hypertension, insulin resistance, and type 2 diabetes mellitus. 32, 33 Skeletal muscle fat infiltration (myosteatosis) has also been related to endothelial dysfunction and oxidative stress. 34 Interestingly, myosteatosis increases with age 35 and it has been recognized as a risk factor for impaired longevity, related to higher all-cause and CV disease mortality. 36 The associations between myosteatosis and CV diseases, as well as the potential coexistence of excessive perirenal and intramuscular fat, should be investigated.
There is a growing interest on the potential role of these abnormal peri-or intra-organ fat (APIFat) deposits as therapeutic targets with more data available for NAFLD. In this context, apart from lifestyle measures to reduce weight and consequently excessive adiposity, statins have been shown to improve biochemical and histological features of NAFLD. 37, 38 With regard to antidiabetic drugs, metformin and pioglitazone have been reported to beneficially affect NAFLD, 39, 40 whereas sitagliptin has been shown to have no impact on liver fat content. 41 Limited randomized controlled trials exist on the effects of the newer antidiabetic drugs on NAFLD including the Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes (E-LIFT) trial, 42 the Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients (EFFECTII) with dapagliflozin, 43 and the Liraglutide Efficacy and Action in NASH (LEAN) study, 44 highlighting the need for further studies. Based on the above data, there are peri-and intra-organ excessive fat depositions linked to increased CV risk, including NAFLD, NAFPD, myosteatosis, epicardial, perirenal, and perivascular fat. [45] [46] [47] It should be noted that APIFat is actually "orthotopic" 48 and not "ectopic" fat, since the latter means "outside its usual place." 49 Adipose tissue is normally located in these regions but when such fat depots accumulate excessively, they can also become dysfunctional, secreting several pro-inflammatory and proatherogenic factors. 50 Further research is needed to elucidate the interrelationships between these fat depots and their role as potential therapeutic targets in reducing cardiometabolic risk. Whether the coexistence of 2 or more fat depots increases CV risk remains to be established.
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